NCT06575959View on ClinicalTrials.gov

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 8, 2025

Conditions
Hepatic InsufficiencyHepatic Impairment
Interventions
DRUG

Enlicitide

Oral tablet

Trial Locations (2)

32809

Orlando Clinical Research Center ( Site 0002), Orlando

78215

The Texas Liver Institute ( Site 0001), San Antonio

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06575959 - A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030) | Biotech Hunter | Biotech Hunter